The adenovirus vector expressing the dominant negative mutant of IKKβ was also found to be a viable anti-cancer therapy and sensitized human prostate carcinoma cells, neuroblastoma cells, and lung cancer cells to TRAIL- or TNF-induced apoptosis, suggesting that targeting NF-κB at the level of IKKβ through the use of adenoviral vectors appears promising [192,193,194]. Here, IKBKB is linked to prostate carcinoma.